GlaxoSmithKline Announces Recall of Blood Pressure Drug

GlaxoSmithKline Announces Recall of Blood Pressure DrugGlobal pharmaceutical company GlaxoSmithKline (GSK) has announced a recall of one of its blood pressure drugs that is manufactured at the Novartis plant located near Lincoln, Nebraska.

According to the Lincoln Journal Star, the company recently announced the recall of 394,230 bottles of the blood pressure drug DynaCirc CR. Although the company has not received any complaints of contamination or tablet mix-ups, the U.S. Food and Drug Administration reported in late February that the medicines were being taken off the shelves "due to compliance concerns regarding the level of [good manufacturing] compliance and procedural controls related to line clearance during the packaging process at the Novartis Consumer Health site."

The recall marks the second action taken by GSK to recall drugs manufactured at the Novartis plant since the beginning of the year. In early January, Novartis was forced to recall a number of its over-the-counter drugs, including  Excedrin, Bufferin, GasX and NoDoz, due to potential packaging mix-ups.

The following day, the FDA warned the public that pain medications manufactured at the Novartis plant for Endo Pharmaceuticals could possibly have been tainted by other products. However after the warning, the FDA fell short of mandating a recall, the media outlet stated.

According to Reuters, the London-based pharma company announced it is unsure when the Novartis facility will be up and running, as it was temporarily shutdown last month to make improvements. The FDA first demanded the work stoppage at the plant in December, when it released a heated report that documented numerous violations and poor quality control procedures.

GSK spokesman Kevin Colgan stated that in response to the latest recall, the company will ensure that alternative treatments are available to patients who are currently taking DynaCirc for high blood pressure.